In rheumatoid arthritis, which cell type is the primary source of TNF-α and IL-6 within the inflamed synovium, driving chronic inflammation and joint destruction?

Explanation

## Cellular Sources of Inflammatory Cytokines in RA Synovium **Key Point:** Synovial fibroblasts and macrophages are the primary producers of TNF-α and IL-6 in the RA synovium. These cytokines are central to the pathogenesis of chronic inflammation, pannus formation, and bone/cartilage destruction. **High-Yield:** The TNF-α/IL-6 axis in RA: - TNF-α activates endothelial cells, promotes leukocyte recruitment, and induces metalloproteinases (MMPs) for matrix degradation - IL-6 drives systemic inflammation, B cell differentiation, and acute phase protein production - Both cytokines activate osteoclasts, leading to bone erosion - Biologic DMARDs (TNF inhibitors, IL-6 inhibitors) target these pathways ### Cellular Contributions to RA Inflammation | Cell Type | Primary Cytokines | Role in RA | | --- | --- | --- | | Synovial fibroblasts | TNF-α, IL-6, IL-8, GM-CSF | Produce MMPs; activate other cells; form pannus | | Macrophages | TNF-α, IL-6, IL-1, IL-12 | Antigen presentation; amplify inflammation | | CD4+ T cells | IFN-γ, IL-17, TNF-α | Th1/Th17 differentiation; B cell help | | B cells/Plasma cells | Antibodies (RF, anti-CCP); IL-6 | Immune complex formation; some cytokine production | | CD8+ T cells | IFN-γ, TNF-α | Minor role; not primary drivers | | Neutrophils | Proteases, ROS | Tissue damage; secondary responders | **Clinical Pearl:** TNF inhibitors (infliximab, adalimumab) and IL-6 inhibitors (tocilizumab) are highly effective in RA because they block the dominant cytokines produced by synovial fibroblasts and macrophages. **Mnemonic:** **FM = Fibroblasts + Macrophages = Factory of TNF/IL-6** in the RA joint.